PNT News and Press, POINT Biopharma Global Inc. From 10/17/22

PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA submission for PNT2001 program in H1 2023 INDIANAPOLIS, Oct. 17, 2022 (GLOBE NEWSW...

INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the closing of its pr...

Truist has initiated POINT Biopharma Global as a buy citing the potential of PNT2002, its prostate cancer therapy candidate in phase 3. The firm has a $22 price target (~161% upside based on Thursday's close). Analyst Nicole Germino said that PNT2002 is de-risked based on key ...

Investors were not kind to Point Biopharma Global (NASDAQ: PNT) on Wednesday. The specialty biotech saw its share price crumble by more than 12% on the day, in sharp contrast to the marginal gain of the S&P 500 index. The major culprit was a new financing move announced by t...

POINT Biopharma Global ( NASDAQ: PNT ) shares dropped 9.6% after-hours on Tuesday after pricing its public offering of 13.9M shares of common stock at a public offering price of $9.00/share for expected gross proceeds to be ~$125M. Underwriters are granted a 30-da...

INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the pricing of its pu...

POINT Biopharma Global ( NASDAQ: PNT ) has announced that it has commenced an underwritten public offering of its common stock. In addition, underwriters were granted a 30-day option to purchase up to an additional 15% of its common stock being sold in the offering at the ...

INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced that it has commenced...

Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A best radiographic objective response (CR, PR) was achieved in 60% of the 10 participants with evaluable disease at baselin...

Radiopharmaceutical company Point Biopharma Global Inc. ( NASDAQ: PNT ) dropped ~28% after the biotech announced the publication of an abstract containing initial data from a Phase 3 trial for its radioligand agent PNT2002. The data from the lead-in cohort of the multi-c...